Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

E-Prescribing Draft Rule Proposes Adoption Of Formulary Info Standards

This article was originally published in The Pink Sheet Daily

Executive Summary

The proposal would establish standards for delivering formulary information based on an RxHub protocol. Under the rule, formulary transmissions would include information on coverage, preferred alternative drugs and comparative copayments.

You may also be interested in...



AHRQ Study On E-Prescribing Cost-Effectiveness Proposed In House Bill

An Agency for Healthcare Research & Quality study would assess the ability of e-prescribing to reduce medical errors under legislation introduced by Rep. Bilirakis (R-Fla.). The bill heads to the House Energy & Commerce Committee after clearing the Health Subcommittee.

AHRQ Study On E-Prescribing Cost-Effectiveness Proposed In House Bill

An Agency for Healthcare Research & Quality study would assess the ability of e-prescribing to reduce medical errors under legislation introduced by Rep. Bilirakis (R-Fla.). The bill heads to the House Energy & Commerce Committee after clearing the Health Subcommittee.

E-Prescribing Comments On Broad Preemption Difficult To Evaluate, CMS Says

Industry representatives who filed comments on the e-prescribing “foundation standards” draft rule favored broader preemption than proposed by the Centers for Medicare & Medicaid Service, but did not specify exactly what they sought to preempt, agency advisor Kocot says.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel